Moisan S, Harvey N, Beaudry G, Forzani P, Burhop K E, Drapeau G, Rioux F
Research Center (Laval University), Hôtel-Dieu de Québec, Canada.
Peptides. 1998;19(1):119-31. doi: 10.1016/s0196-9781(97)00273-8.
A rat blood pressure assay was used to perform a structure-activity relationship study (SAR) of Leu-Val-Val-hemorphin-7 (LVV-H7), a fragment of hemoglobin (Hb) beta-chain, elucidate the mechanisms of its cardiovascular effects, and test its potential involvement in the pressor activity of diaspirin crosslinked Hb (DCLHb), a recently developed Hb-based oxygen carrier. The SAR study revealed that the C-terminal-Arg-Phe-amino acid sequence of LVV-H7 contained the main determinants of the pressor activity of this peptide. Drug interaction studies using various inhibitory drugs (e.g., phentolamine, clonidine, etc.) and LVV-H7 showed that the pressor effect and tachycardia elicited by LVV-H7 involved the activation of the sympathetic nervous system (SNS). Additional studies using phenytoin (sodium channel blocker), [Tic7]H7(5-7)-NH2 (putative antagonist of receptors for LVV-H7) and H7(5-7)-NH2, an amidated C-terminal fragment of LVV-H7, suggested that LVV-H7 activated the SNS by interacting with specific receptors functionally coupled with phenytoin-sensitive sodium channels. The pressor effect and tachycardia caused by LVV-H7 were potentiated by captopril, suggesting that the angiotensin converting enzyme may contribute to the inactivation of LVV-H7 in rats. The pressor activity of DCLHb, in contrast to that elicited by LVV-H7, was not affected by animal pretreatment with LVV-H7 fragments shown to inhibit the pressor effect of LVV-H7. We conclude that: 1) LVV-H7 is unlikely to mediate the pressor activity of DCLHb in rats; 2) the pressor and tachycardic activities of LVV-H7 are mediated by the SNS; 3) the C-terminal-Arg-Phe-amino acid sequence of LVV-H7 contains the chemical groups responsible for the pressor effect of this peptide in rats; 4) LVV-H7 and FMRF amide-related peptides may share the same mechanism of pressor activity in rats.
采用大鼠血压测定法对血红蛋白(Hb)β链片段亮氨酸-缬氨酸-缬氨酸-血啡肽-7(LVV-H7)进行构效关系研究(SAR),阐明其心血管效应机制,并测试其是否可能参与了最近开发的基于血红蛋白的氧载体双阿司匹林交联血红蛋白(DCLHb)的升压活性。构效关系研究表明,LVV-H7的C末端-精氨酸-苯丙氨酸氨基酸序列包含该肽升压活性的主要决定因素。使用各种抑制性药物(如酚妥拉明、可乐定等)和LVV-H7进行的药物相互作用研究表明,LVV-H7引起的升压效应和心动过速涉及交感神经系统(SNS)的激活。使用苯妥英(钠通道阻滞剂)、[Tic7]H7(5-7)-NH2(LVV-H7受体的假定拮抗剂)和H7(5-7)-NH2(LVV-H7的酰胺化C末端片段)进行的进一步研究表明,LVV-H7通过与功能上与苯妥英敏感钠通道偶联的特定受体相互作用来激活SNS。卡托普利增强了LVV-H7引起的升压效应和心动过速,表明血管紧张素转换酶可能有助于大鼠体内LVV-H7的失活。与LVV-H7引起的情况相反,DCLHb的升压活性不受预先用已证明可抑制LVV-H7升压效应的LVV-H7片段处理动物的影响。我们得出以下结论:1)LVV-H7不太可能介导大鼠体内DCLHb的升压活性;2)LVV-H7的升压和心动过速活性由SNS介导;3)LVV-H7的C末端-精氨酸-苯丙氨酸氨基酸序列包含负责该肽在大鼠体内升压效应的化学基团;4)LVV-H7和FMRF酰胺相关肽在大鼠体内可能具有相同的升压活性机制。